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MTA1 promotes metastasis of MPM via
suppression of E-cadherin
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Abstract
Background: Metastasis-associated gene 1(MTA1) has been identified as an oncogene in many tumors, and
aberrant MTA1 expression has been linked to carcinogenesis and metastasis. We aim to investigate the mechanism
of MTA1 and metastasis in malignant pleural mesothelioma (MPM).
Methods: Real-time polymerase chain reaction (PCR) and immunohistochemical staining were employed to detect
MTA1 and E-cadherin expression in MPM tissues and corresponding adjacent tissues. Stable clone with knock-down
of MTA1 was generated with shRNA via lentivirus technology in MPM cell lines. Wound-healing assay, transwell
assay and PCR array were carried out for detecting invasion and migration of MPM cells. Luciferase reporter assay
was performed to validate the effect of MTA1 on E-cadherin.
Results: MTA1 expression is up-regulated in MPM and shown a negative correlation with E-cadherin expression.
MTA1 could enhance the invasion and migration of MPM cells via suppressing the expression of E-cadherin. MTA1
overexpression is associated with pathology, metastasis and survival rate of MPM patients.
Conclusions: MTA1 plays an important role in Epithelial-to-mesenchymal transition (EMT) to promote metastasis via
suppressing E-cadherin expression, resulting in a poor prognosis in MPM. MTA1 is a novel biomarker and indicative
of a poor prognosis in MPM patients.
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Background
Malignant pleural mesothelioma (MPM) is considered as
one of the highest aggressive tumor arising from the cells
lining serosal cavities, mostly resulting from the occupa-
tional exposure to asbestos fibers [1]. Although great ef-
forts have been made toward improving diagnosis and
treatment [2], there are no efficacious therapies for MPM
patients presently, and therefore the overall survival is ex-
tremely poor. Thus, the investigation of developing the
novel therapeutics, especially molecular targeting therapy,
is very important for the patients with MPM.
MTA (metastasis-associated gene) is a newly discovered
family of cancer progression-related genes and their
encoded products. MTA are integral parts of nucleosome
remodeling and histone deacetylation (NuRD) complexes,
function as transcriptional co-repressors which regulate
varieties pathways, including hormonal action, epithelial-
to-mesenchymal transitions, differentiations, protein sta-
bility and development [3, 4]. MTA1, the first gene found
in this family, has been repeatedly reported to be overex-
pressed along with its protein product MTA1 in a wide
range of human cancers such as endometrial adenocarcin-
omas, gastrointestinal carcinoids, colorectal carcinomas,
hepatocellular carcinomas and non-small cell lung cancers
[5–10]. However, the potential prognostic relevance of
MTA1 expression in MPM has not yet been investigated.
In this study, we aim to investigate the role of MTA1
in the pathogenesis of MPM and identify MTA1 could
promote the metastasis of MPM cells by repressing the
expression of E-cadherin.
Methods
Patients and tissue samples
MPM and corresponding adjacent tissues employed in this
study were obtained from 65 consecutive patients who
had de novo disease and undergone surgical resection.
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They were included between December 2008 and
November 2013 at the First Affiliated Hospital of
Soochow University (Suzhou, China) and the First
Affiliated Hospital of Nanjing Medical University (Nanjing,
China). The patients were followed up for a median period
of 12 months (range, 3–28 months) after operation and
their complete clinical data were collected. The correct
diagnosis was assessed by an experienced pathologist and
the staging of MPM by a clinical oncologist according to
AJCC/UICC Guidelines version 7.2010 MPM. Adjacent tis-
sue was located within 3 cm of the edge of the tumor tissue
(Additional file 1: Fig. 1S). The study was approved by the
Ethical Committee of the First Affiliated Hospital of
Soochow University (Suzhou, China) and the First Affiliated
Hospital of Nanjing Medical University (Nanjing, China),
and written informed consent was obtained from the each
patient.
DNA and RNA preparation
Total RNA was extracted from fresh frozen tissue speci-
mens using TRIzol method (Invitrogen, Shanghai, China)
and RNA quality was detected by NanoDrop 2000 and
A260/A280 was between 1.95 and 2.05. cDNA was syn-
thesized using reverse transcriptase kit (TAKARA, Tokyo,
Japan) according to the manufacturers’ protocol.
Real-time PCR analysis
MTA1 and E-cadherin mRNA levels were measured by
real-time PCR using SYBR Premix Ex Taq (TAKARA,
Tokyo, Japan). MTA1 and E-cadherin transcription
values were normalized against the expression of β-
actin. Amplification conditions, primers, and probes se-
quences for MTA1 and β-actin were from the work by
Zhu X et al. [9] and for E-cadherin were the same as
those in the work by Martínez-Estrada et al. [11]. All
procedures are in agreement with MIQE guidelines.
Cell culture
MSTO-211H, NCI-H2452 and 293 T cell lines (ATCC,
Manassas, VA) were employed for the present study.
MSTO-211H and H2452 were origin from the patients
with mesothelioma and cultured in RPMI 1640 medium
supplemented with 10 % fetal bovine serum (Invitrogen,
Carlsbad, CA), while 293 T were origin from human em-
bryonic kidney cells and cultured in DMEM high glu-
cose medium supplemented with 10 % fetal bovine
serum. All cells were maintained in a humidified 37 °C
incubator with 5 % CO2.
Lentivirus production and transduction
To generate plasmid-expressing MTA1-shRNA, double-
stranded oligonucleotides were cloned into pLL3.7 vec-
tor (gifted by D. Yun Chen, Nanjing Medical University,
China) and named pLL3.7-shMTA1. The sequences of
MTA1-shRNA used are ccggtGACCACCGACAGATAC
GTG ttcaagaga CACGTATCTGTCGGTGGTCTTTTT
Tg. The uppercase letters represent MTA1-specific se-
quence, and lowercase letters represent hairpin sequences.
Recombinant lentivirus was generated from 293 T cells
using calcium phosphate precipitation. MSTO-211H and
H2452 were transfected with lentivirus using polybrene
(8 μg/ml).
Western-blotting assay
Proteins were extracted from cultured cells, quantitated
using a protein assay (bicinchoninic acid [BCA] method;
Beyotime, Shanghai, China). Proteins were fractionated
by sodium dodecyl sulfate polyacrylamide gel electrophor-
esis, transferred to polyvinylidene fluoride (PVDF) mem-
brane, blocked in 4 % dry milk at room temperature for
1 hour, and immunostained with primary antibodies at 4 °C
over-night using anti-MTA1 (1:2000, Abcam, Cambridge,
MA), anti-E-cadherin (1:1000; Abcam, Cambridge, MA),
and anti-GAPDH (1:1000, Kangchen,China). The results
were visualized via a chemiluminescent detection system
(Pierce ECL Substrate Western blot detection system;
Thermo, Rockford, IL) and exposed in Molecular Imager
ChemiDoc XRS System (Bio-Rad, Hercules, CA).
Cell proliferation assay
Cells were seeded into 96-well plates (6.0 × 103 cells per
well). Cell viability was assessed by cell-counting kit-8
assay (CCK-8, Beyotime, Shanghai, China). The absorb-
ance of each well was read on a spectrophotometer
(Thermo) at 450 nm (A450). Five independent experi-
ments were performed in quintuplicate.
Wound-healing assay
Cells were seeded in six-well plates and cultured to con-
fluence. Wounds of 2-mm width were created with a
plastic scriber and the floating cells were washed away
thrice with phosphate buffered saline (PBS). After incu-
bation in a serum-free medium for 48 hours, cultures
were observed and photos were taken under a micro-
scope. A minimum of five randomly chosen areas was
measured.
Transwell invasion assay
The invasive ability of the cells was investigated using
Transwells (8-μm pore size; Corning Costar Corp, Bedford,
MA) put into the 24-well plates. First, 50 μl Matrigel
(50 μg/ml; BD Biosciences, San Jose, CA) was added onto
each surface of the chamber, incubated for 2 hours for so-
lidification, then the supernatant was washed away with
warm PBS. MSTO-211H and H2452 were suspended in
RPMI 1640 containing 2 % fetal bovine serum. A total of
100 μl of the cell suspension (5 × 104 cells) was added to
the upper chamber coated with Matrigel, and 400 μl of
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RPMI 1640 containing 10 % fetal bovine serum was added
to the lower compartment. After incubation for 48 hours at
37 °C in a 5 % CO2 humidified incubator, the Matrigel and
cells on the upper surface of the filter were removed with
cotton swabs and the cells that invaded into the lower sur-
face were fixed with 2 % paraformaldehyde, stained with
crystal violet. Then the filters were removed from the
chambers, air-dried on the precleaned slides and applied
with cover-slides using resina. Images were taken under
an inverted microscope (Olympus Corp, Tokyo, Japan)
at × 100 magnifications over three random fields in each
well. ImageJ 1.45 s software (National Insititutes of Health,
Bethesda, MD) was used for integrated optical density
analysis. Each experiment was performed in triplicate.
RT-PCR array
Total RNA was extracted from MSTO-211H, MSTO-
211H-shMTA1, H2452 and H2452-shMTA and reverse
transcribed to cDNA. Subsequently, cDNA was amplified
by PCR using 23 Super Array PCR master mix (SuperArray
Bioscience, Frederick, MD) and then RT-PCR was carried
out using the Human Tumor Metastasis RT2 Profiler PCR
array (SuperArray Bioscience, Frederick, MD) in an ABI
PRISM7900 system (Applied Biosystems, Foster City, CA),
according to the manufacturer’s instructions.
Luciferase report assay
The promoter of E-cadherin was synthesized artificially
and cloned into the luciferase reporter vector (Promega,
Madison, WI). MSTO-211H and H2452 cells were seeded
into 24-well plates and cotransfected with MTA1-siRNA
(pooled siGENOME SMART pool MTA1 siRNA [50 nM
per well]; Dhamacon, Chicago, IL), and luciferase reporter
vectors using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA), following the instructions. Zero, 12 and 24 hours
after incubation, cells were collected and firefly and
Renilla luciferase activity was measured with the dual-
luciferase reporter assay system (Promega). All results
were gained through three independent experiments.
TGF-β1 Inducing EMT of MPM cells
The MPM cells were cultured in vitro and induced by
transforming growth fact beta1 (TGF-β1, 5 ng/ml) for
0 h, 24 h, 48 h. The morphological characteristics of
cells were observed by microscope (Olympus Corp,
Tokyo, Japan) and the expression of MTA1 was detected
by real-time PCR.
Immunohistochemical staining
Tissues were fixed in 4 % paraformaldehyde and cut
from paraffin block to 5 μm thickness. After dewaxing
with xylene and rehydration with a graded series of etha-
nol, the slides were heated in the autoclave for three
minutes using citrate buffer (PH 6.0) and incubated with
primary antibody MTA1 (1:1000, Abcam, Cambridge,
MA), E-cadherin (1:1000; Abcam, Cambridge, MA) at
4 °C overnight. Blocking serum or antibody dilution buf-
fer was prepared as Negative controls. The primary anti-
bodies utilized were all the same as for Western blot
analysis. Photographs were taken by microscope (Nikon,
ECLIPSE 50i) and software NIS-Elements v4.0. Average
values of integrated optical density (IOD) were obtained
from five random fields per slide by using Image-Pro
Plus software (v5.0). Every data was detected three times
at least.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
(version 5.01; GraphPad Software, Inc, La Jolla, CA) stat-
istical software. The Student’s t test and paired t test
were used to analyze significance between independent
groups and paired materials, respectively. The correl-
ation test was used to analyze the correlation between
MTA1 and E-cadherin. The χ2 test was used to test the
significance of observed differences in proportions ex-
cept when the cells size was less than 5 (Fisher’s exact
tests). The significance was accepted as p value was less
than 0.05.
Results
MTA1 expression is up-regulated in MPM and shown a
negative correlation with E-cadherin expression
We investigated 65 pairs of MPM and corresponding
adjacent specimens using real-time PCR and immuno-
histochemistry. MTA1 RNA level in MPM was signifi-
cantly higher compared to adjacent tissues (p < 0.0001;
Fig.1a). However, E-cadherin RNA level was just con-
trary (p < 0.0001; Fig.1b). Moreover, a negative correl-
ation was observed between MTA1 and E-cadherin
expression in MPM samples (r = − 0.6250; p < 0.0001;
Fig. 1c). To further evaluate the correlation between
MTA1 and E-cadherin expression, two cases with differ-
ent MTA1 expression levels are shown in Fig. 1d: CASE
1 (strong positive) and CASE 2 (weak positive). The
level of E-cadherin was down-regulated in CASE 1 com-
pared to CASE 2. Additionally, statistical analysis of
IOD values stained with E-cadherin in MTA1-high
group and MTA1-low group are shown in the histogram
in Fig. 1e and f (p < 0.0001). The results suggested that
MTA1 expression was up-regulated and negatively cor-
related to E-cadherin expression in MPM.
MTA1 could enhance the invasion and migration of MPM
cells in vitro
In vitro, both two MPM cell lines (MSTO-211H and
H2452) were transduced by pLL3.7-shMTA1 and de-
tected the expression of MTA1 by real-time PCR and
Western-blot (Fig. 2a, b, and c). These results indicated
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Fig. 1 Expression and correlation of MTA1 and E-cadherin transcripts in MPM patients. a Significantly higher RNA expression of MTA1 in tumor
specimens than in the adjacent tissue samples (p< 0.001). b Significantly decreased RNA expression of E-cadherin in tumor specimens in comparison with
adjacent tissues (p< 0.001). c A negative correlation between MTA1 and E-cadherin in tumor samples (r=−0.5482, p< 0.0001). d Immunohistochemical
staining of E-cadherin in MTA1 overexpression tumor tissue (CASE 1) and MTA1 low expression tumor tissue (CASE 2) in vivo. Data are represented as
mean ± SD. *p< 0.05, **p< 0.001. e and f Average value of integrated optical density (IOD) of E-cadherin in MTA1-high group and MTA1-low group were
assessed by analyzing five fields per slide and recorded in the histogram. MTA1, metastasis-associated gene 1; MPM, malignant pleural mesothelioma
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Fig. 2 (See legend on next page.)
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expression of MTA1 was significantly reduced by the
lentivirus. As illustrated, the invasion and migration abil-
ities of both MSTO-211H and H2452 were evidently
suppressed when MTA1 was down-regulated by pLL3.7-
shMTA1 (Fig. 2d, f, h and i). And the quantification of
the invasion abilities of MSTO-211H and H2452 are
presented in Fig. 2e and g corresponding with Fig. 2d
and f. Moreover, We found that MTA1 silencing could
not affect cell proliferation (Fig. 2j and k).
MTA1 knockdown induces increase of E-cadherin
expression in MPM cells
A variety of EMT genes were screened out after MTA1
down-regulation via the PCR array and nine genes
whose variation larger than two folds were picked. Then
we verified the expression of these nine genes in 65 sam-
ples by real-time PCR. We found E-cadherin was up-
regulated most after MTA1 silenced in both MSTO-211H
and H2452 (Fig. 3a and b). In order to confirm the nega-
tive regulatory effect of MTA1 on E-cadherin, we also de-
tected the E-cadherin protein in both two cells by
Western-blot. As shown in Fig. 3c, E-cadherin protein ex-
pression was increased significantly in both two cells
transduced by pLL3.7-shMTA1. Subsequently, we per-
formed luciferase report assay in MSTO-211H and H2452
transfected with MTA1-siRNA and the luciferase activity
of E-cadherin was enhanced significantly with transfection
time increases (Fig. 3d and e). Moreover, we found the
mRNA expression of MTA1 was up-regulated in TGF-β1-
stimulated MPM cells (Fig 3f) which was according with
the result of Suresh B et al. [12]. Taken together, these
findings suggest that the decreased expression of MTA1
could enhance E-cadherin expression in MPM cells.
MTA1 overexpression is associated with a poor prognosis
of MPM
A total of 65 MPM tissues were divided into two
groups using a semiquantitative immunoreactivity scor-
ing system (IRS), as reported elsewhere [9, 10, 13, 14].
Concomitant cytoplasmicstaining was not counted. Cat-
egory A documented the intensity of immunostaining as 0
(no immunostaining), 1(weak immunostaining), 2 (moder-
ate immunostaining), and 3 (strong immunostaining).
Category B documented the percentage of immunoreac-
tive cells as 0 (none), 1 (<10 %), 2(10–50 %), 3 (51–80 %),
and 4 (80 %). Multiplication of categories A and B resulted
in an IRS ranging from 0 to 12 (negative [IRS, 0] versus
weak [IRS, 1–4] versus moderate [IRS, 5–8] versus strong
[IRS, 9–12]) for each tumor. Both percent positivity of
cells and staining intensity were decidedin a double-
blinded manner. Interobserver and intraobserver variabil-
ity was negligible. Tumors with moderate or strong ex-
pression (IRS 4) were considered to show MTA1
overexpression, whereas tumors with negative or weak ex-
pression (IRS < 4) were considered to show MTA1 down-
expression. The relationship of MTA1 expression levels
and clinicopathological features were shown in Table 1.
Significant higher TNM stage (p < 0.01), metastasis (lymph
node metastasis and distant metastasis, p < 0.01) were ob-
served in high-MTA1 expression group. We also found
MTA1 level in sarcomatoid and biphasic malignant me-
sotheliomas were higher than the level in epithelioid ma-
lignant mesothelioma (p < 0.05). There was no correlation
between MTA1 expression level and sex, age, as shown in
Table 1. Additionally, our findings indicated that MPM
patients with a high expression level of MTA1 had a sig-
nificantly shorter overall survival compared with pa-
tients with a low expression level of MTA1 and
10 months median survival compared with 19 months
median survival after operation (p < 0.01, Fig. 3g).
These results strongly indicate that MTA1 overexpres-
sion contribute to the poor prognosis of MPM patients.
Discussion
Malignant pleural mesothelioma (MPM), one of the most
deadly human carcinomas, is an aggressive tumor which
originates from the mesothelial cells of serosal tissues [15].
Metastasis is the major cause of treatment failure in pa-
tients with MPM and its molecular mechanisms are still
not clear and are under intensive investigation. To eluci-
date the mechanisms of metastasis is essential for improv-
ing surgery and treatment outcome, especially for
selecting and customizing chemotherapy.
In this study, for the first time, we reported that MTA1
gene and protein in MPM specimens was markedly up-
regulated compared to adjacent tissues, and MTA1 could
(See figure on previous page.)
Fig. 2 MTA1 enhances the invasion and migration in MPM cells. a and b MTA1 level of MPM wild-type cells (MSTO-211H and H2452) and MPM
cells transfected by lentivirus containing pLL3.7-empty and pLL3.7-shMTA1 by real-time PCR. c MTA1 expression of MPM wild-type cells (MSTO-211H
and H2452) and MPM cells transfected by lentivirus containing pLL3.7-empty and pLL3.7-shMTA1 by western-blot. d and e The result of transwell assay
showed that the invasion ability of MSTO-211H was significantly suppressed after MTA1 silencing, which was confirmed by integrated optical density
(IOD) value evaluation. f and g Similar effect of MTA1 was observed in H2452 MPM cells. h and i The result of wound-healing assay showed that the
migration ability of MPM cells was restrained after MTA1 silencing at 48 h time point. Data are represented as mean ± SD. *p < 0.05, **p < 0.001.
j and k, The viability of MPM wild-type cells (MSTO-211H and H2452) and MPM cells transfected by lentivirus containing pLL3.7-shMTA1 were
assessed by CCK-8 assay at 0 h, 24 h, 36 h and 48 h time point. MTA1, metastasis-associated gene 1; MPM, malignant pleural mesothelioma;
PCR, polymerase chain reaction; CCK-8, cell-counting kit 8
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enhance the metastasis of MPM cells by direct regulation
of E-cadherin. Additionally, the relationship of MTA1
level and clinicopathological features in Table 1 sug-
gests that MTA1 overexpression was associated with
the poor prognosis of MPM patients. With all findings
taken together, we hypothesized that MTA1 potentially
play an oncogenic role in promoting metastasis of
MPM.
MTA1 has been considered to be related with the
poor prognosis due to increase the migration and in-
vasion of various tumors [6, 8, 16–19]. As a dual func-
tion co-regulator, MTA1 operates as a transcriptional
repressor of ER-α,BRCA1 and p21 and as a transcrip-
tional activator of BCAS3 and Pax5 [20–24]. Some
studies have indicated that down-regulation of MTA1
by RNAi leads to an increase expression of E-cadherin
which acts as a key role in epithelial-to-mesenchymal
transition in cancer cells [25–27]. Moreover, Wenhao
Weng et al. have elucidated that MTA1, together with
Snail or Slug, acted to directly repress the promoter ac-
tivity of E-cadherin in ESCC (esophageal squamous cell
carcinoma) cells very recently [28]. Coincidentally, we
verified that MTA1 could enhance the epithelial-to-
mesenchymal transition by repressing the promoter activ-
ity of E-cadherin in MPM cells.
Epithelial-to-mesenchymal transition (EMT) is a cel-
lular process which is considered to be involved in
embryo-morphogenesis, fibrosis and tumor metastasis
[29, 30]. EMT could enhance not only the ability of
migration and invasion, but also the resistance to
apoptosis, senescence and drug resistance in cancer
[31]. EMT process always accompany by a reduced
expression of E-cadherin, cyto-keratins (CK), and β-
catenin (in the membrane), and an increased expres-
sion of Snail, Slug, Twist, ZEB1, ZEB2, N-cadherin,
vimentin, a-smooth muscle actin (aSMA), S100A4, and
matrix metalloproteinases (MMP) [31–33]. In particu-
lar, repressing the gene expression of E-cadherin could
notably promote the EMT which is considered as a
primary reason of tumor metastasis. According to our
study, the poor prognosis of patients with high
MTA1expression was correlated with E-cadherin, the
very classical metastasis suppressor.
Conclusion
Our study identified the negative correlation of MTA1
and E-cadherin in 65 MPM cases, both of which were
associated with TNM stage, metastasis and histological
types and proved the regulatory function of MTA1 on E-
cadherin through direct binding of its promoter. How-
ever, as a limit of the number of MPM cases and cell
types, more elaborate research will be requireda for fur-
ther exploration of MTA1 in tumorigenesis and metasta-
sis. Thus, MTA1 potentially served as a therapeutic
target for the treatment of MPM.
(See figure on previous page.)
Fig. 3 MTA1 suppressed the expression of E-cadherin and was up-regulated by TGF-β1 inducing. a and b Nine metastasis genes varied larger
than two folds were picked via PCR array and were verified by real-time PCR in MPM cells. c Western-blot assay validated the result of PCR array
of negative trend of MTA1 and E-cadherin in MPM cells. d and e Luciferase report assay demonstrated that E-cadherin transcription was gradually
enhanced in MPM cells transfected by lentivirus containing pLL3.7-shMTA1 in a time-dependent manner. f MTA1 mRNA expression was up-regulated
in TGF-β1-stimulated MPM cells. g MPM patients with a high expression level of MTA1 had a significantly shorter overall survival compared with
patients with a low expression level of MTA1. Data are represented as mean ± SD. *p < 0.05, **p < 0.001. MTA1, metastasis-associated gene 1; MPM,
malignant pleural mesothelioma; TGF-β1, transforming growth factor beta 1; PCR, polymerase chain reaction
Table 1 Correlation of MTA1 expression and clinicopathological
features of MPM
Characteristics All patients MTA1 expression P
Low High χ2
N 65 25 40
Sex 0.455 0.559
Male 35 12 23
Female 30 13 17
Age (years) 0.842 0.040
<60 27 10 17
≥60 38 15 23
Histology 0.038 6.524
Epithelioid 20 13 7
Sarcomatoid 25 7 18
Biphasic 20 5 15
TNM stagea 0.003 8.990
I/II 29 17 12
III/IV 36 8 28
Lymph node Metastasis 0.001 11.714
Yes 38 8 30
No 27 17 10
Distant Metastasis <0.001 14.562
Yes 35 6 29
No 30 19 11
aTNM stage was based on AJCC/UICC Guidelines version 7.2010 MPM. MTA1,
metastasis-associated protein 1; MPM, Malignant pleural mesothelioma
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Additional file
Additional file 1: Figure 1S. MTA1 protein expression in tumor tissue
and adjacent tissue of one MPM patient. A and B, immunohistochemical
staining of MTA1 in tumor specimen in comparison with adjacent tissue.
(TIF 2636 kb)
Abbreviation
MTA: Metastasis-associated gene; MTA1: Metastasis-associated gene 1;
MPM: Malignant pleural mesothelioma; PCR: Polymerase chain reaction;
EMT: Epithelial-to-mesenchymal transition; NuRD: Nucleosome remodeling
and histone deacetylation; CK: Cyto-keratins; aSMA: A-smooth muscle actin;
MMP: Matrix metalloproteinases.
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